- Home
- SLND vs BMEA Comparison
SLND vs BMEA Comparison
Compare SLND & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- BMEA
- Stock Information
- Founded
- SLND 1900
- BMEA 2017
- Country
- SLND United States
- BMEA United States
- Employees
- SLND N/A
- BMEA N/A
- Industry
- SLND Military/Government/Technical
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- SLND Industrials
- BMEA Health Care
- Exchange
- SLND Nasdaq
- BMEA Nasdaq
- Market Cap
- SLND 151.1M
- BMEA 153.3M
- IPO Year
- SLND N/A
- BMEA 2021
- Fundamental
- Price
- SLND $3.61
- BMEA $4.19
- Analyst Decision
- SLND Buy
- BMEA Buy
- Analyst Count
- SLND 2
- BMEA 13
- Target Price
- SLND $5.50
- BMEA $37.25
- AVG Volume (30 Days)
- SLND 42.3K
- BMEA 1.1M
- Earning Date
- SLND 11-12-2024
- BMEA 10-29-2024
- Dividend Yield
- SLND N/A
- BMEA N/A
- EPS Growth
- SLND N/A
- BMEA N/A
- EPS
- SLND N/A
- BMEA N/A
- Revenue
- SLND $1,029,117,999.00
- BMEA N/A
- Revenue This Year
- SLND $0.91
- BMEA N/A
- Revenue Next Year
- SLND $5.38
- BMEA N/A
- P/E Ratio
- SLND N/A
- BMEA N/A
- Revenue Growth
- SLND N/A
- BMEA N/A
- 52 Week Low
- SLND $1.85
- BMEA $3.61
- 52 Week High
- SLND $6.16
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- SLND 59.27
- BMEA 24.17
- Support Level
- SLND $3.37
- BMEA $3.81
- Resistance Level
- SLND $3.63
- BMEA $6.06
- Average True Range (ATR)
- SLND 0.25
- BMEA 0.56
- MACD
- SLND 0.02
- BMEA -0.14
- Stochastic Oscillator
- SLND 91.46
- BMEA 7.40
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.